感染 (JP Patent Analysis Report)
The Technical Field "感染" had 34 patent application filings in the most recent period (2023-01-01 to 2023-02-28). This is a significantly decreased of -260 filings (-88.4%) over 294 they had in the same period of the previous year (2022-01-01 to 2022-02-28). This report also includes technical terms related to " 伝染 " in the search set.
The highest number of filings in 2021 with 2,913 cases, and their lowest number in 2022 with 1,569 cases.
The mean of the number of filings over the last 5 years (2018 to 2023, 11,518 cases in total) is 1,920, and the median is 2,210. The coefficient of variation (standard deviation/mean) is 0.5, and there have been big fluctuations in the number of filings from year to year.
| Index | Value |
|---|---|
| Average | 1,920 patents |
| Std Dev | 900 |
| COV | 0.5 |
The number of filings has been decreasing for the last 3 years (2020 to 2023).
| Year | Cases | YOY |
|---|---|---|
| 2022 year | 1,569 cases | -46.1 % |
| 2021 year | 2,913 cases | +16.66 % |
| 2020 year | 2,497 cases | +14.49 % |
This report provides the latest patent analysis information (the IP landscape, including a patent map) on the patent search results of the JP patent database for 感染 for the period of the last 10 years (2014-01-01 to 2024-10-31). You can compare the information in this report with the trends in your competitors’ patent filings and technologies, and use it to search for important patents.
This service provides, free of charge, a patent analysis report based on the latest patent data (Japanese, U.S., European, and PCT application publications) for use in patent searches, patent analysis, and IP landscaping. The service is offered by "Patent Integration" a firm specializing in patent search/patent analysis.
This report includes basic information to help you understand the IP strategy and management of 感染, such as changes in the number of patents/patent applications they have filed, comparisons of the numbers of patents/patent applications filed by their peers and competitors, their top coapplicants (joint research partners, alliance partners), and their most important patents. It can be used in various intellectual property business operations such as IP landscaping, patent search/patent analysis, preparation of intellectual property business evaluation reports, selection of M&A candidates, and selection of alliance partners.
He is a patent attorney at a patent office. He specializes in invention counseling, patent filing, and intellectual property strategies for start-up companies and new businesses in the fields of software, information technology and artificial intelligence. He runs a patent course for beginners on Udemy, an online course provider.
After studying physics at the University of Tokyo as a doctoral student, he was engaged in intellectual property analysis and technology trend research as an in-house patent attorney at a precision equipment manufacturer and at Toyota Central R&D Labs. Inc..
Introduction
The concept of the "IP landscape" (IPL) has been attracting attention recently.
An IP landscape is not limited to patent information, but also integrates and analyzes business information (e.g., non-patent information such as papers, news releases, stock information, and market information). Intellectual-property-based business management is realized through the analysis of intellectual property information applied to the formulation of management strategies and business strategies. This is a comprehensive approach that includes but not limited to planning of open and closed strategies, selecting M&A candidates, searching for alliance partners, and formulating intellectual property strategies, through the exploitation of intellectual property information.
IP landscaping usually includes patent search and patent analysis. In patent search and patent analysis, it is important to grasp the market position of each company and the overall technological trends and development trends for each technology. More specifically, it is important to understand what intellectual property your own company and other companies hold, what the strengths and weaknesses of other companies are, and how other companies are trying to exploit their intellectual property. In other words, it is important to understand both the business strategy and the intellectual property strategy of each company.
After reading this search report, you may be interested in more detailed patent searches and patent analysis. We offer a service called Patent Integration, which is an integrated patent search and patent analysis service. With reasonable pricing and a simple user interface such that even beginners can quickly search for and analyze patent information by company or technology from a web browser, please consider using it for detailed patent searches, patent analysis, and IP landscaping.
Patent Integration has a patent-landscaping function that can visually represent a set of tens of thousands of patents/patent applications. This allows you to convincingly show the technical positions of your company and its competitors to your management and business strategists in order to formulate management strategies and business strategies.
感染, Changes in the Number of JP Patents/Patent Applications
The changes in the number of patent filings of 感染 over the last 20 years (JP) are shown below.
The change in the number of patents/patent applications is the most basic index in patent analysis. By examining the change in the number of patents/patent applications, you can see the status of technological development and R&D focus for each company or technology. It should be noted that since there is a one and a half year lag between the filing and the laying open of patent applications, it is not possible to analyze the situation more recently than one and half years prior to the present.
In this report, you can only see the change in the number of patents/patent applications by company or technology, whereas Patent Integration allows you to quickly compare the number of patent applications with your competitors in each technical field by cross-referencing with other keywords and patent classifications.
Search Set (Analysis Patents)
This patent analysis report was created for a patent search set of 20,603 cases retrieved by applying the following search formula and analysis period to the following patent database. Patent information such as a patent analysis result, a patent map, and a patent landscape can be freely used for patent searches, analysis, and work on intellectual property strategies, including IP landscaping.
感染
Same industry / competition company information (JP)
The number of patents and changes in the number of patents of other companies (competitors) in the same industry as 感染 are shown below.
Comparison of changes in the number of patents with peers and competitors is an important analytical index for understanding the intellectual property strategies of each company. By checking the transition of the number of patents for each company / competitor, you can check the status of focus on technology development and R&D for each company / technology.
It should be noted that patents have a time lag of one and a half years from filing to publication, so it is not possible to analyze the situation more recent than one and a half years.
If you want to find out more information, " Patent Integration , You can compare the number of patent applications with competitors in each technical field in a short time by multiplying with other keywords and patent classifications.Please use it for more detailed patent information analysis such as selection of M&A candidate destinations and alliance destinations.
Trends in filing of joint patent applications in the last 3 years (2022 to 2024).
Comparing the number of applications of each company, エフホフマン-ラロシュアーゲー has the highest number of joint applications in the last in the last 3 years (2022 to 2024) with 18 cases, followed by ザリージェンツオブザユニバーシティオブカリフォルニア with 13 cases.
| Name | Cases |
|---|---|
| エフホフマン-ラロシュアーゲー | 18 cases |
| ザリージェンツオブザユニバーシティオブカリフォルニア | 13 cases |
| ギリアードサイエンシーズインコーポレイテッド | 10 cases |
| ノバルティスアーゲー | 8 cases |
| ブリストル-マイヤーズスクイブカンパニー | 8 cases |
| ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング | 8 cases |
| ジェネンテックインコーポレイテッド | 7 cases |
| グラクソスミスクラインバイオロジカルズソシエテアノニム | 4 cases |
Trends in filing of joint patent applications for the target period (2014 to 2024).
Comparing the number of applications of each company, ギリアードサイエンシーズインコーポレイテッド has the highest number of joint applications in the last for the target period (2014 to 2024) with 205 cases, followed by エフホフマン-ラロシュアーゲー with 196 cases.
| Name | Cases |
|---|---|
| ギリアードサイエンシーズインコーポレイテッド | 205 cases |
| エフホフマン-ラロシュアーゲー | 196 cases |
| ノバルティスアーゲー | 155 cases |
| ザリージェンツオブザユニバーシティオブカリフォルニア | 149 cases |
| ブリストル-マイヤーズスクイブカンパニー | 125 cases |
| グラクソスミスクラインバイオロジカルズソシエテアノニム | 109 cases |
| ジェネンテックインコーポレイテッド | 85 cases |
| ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング | 65 cases |
| アメリカ合衆国 | 34 cases |
| グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 5 cases |
| メルク・シャープ・エンド・ドーム・コーポレイション | 3 cases |
Same industry / competition company, Change in the Number of JP Patents
Below is a patent map showing changes in the number of applications for JP patents of 11 companies in the same industry over the past 20 years.
Top company information (JP)
The number of patents and changes in the number of patents of other companies (competitors) in the same industry as 感染 are shown below.
Comparison of changes in the number of patents with peers and competitors is an important analytical index for understanding the intellectual property strategies of each company. By checking the transition of the number of patents for each company / competitor, you can check the status of focus on technology development and R&D for each company / technology.
It should be noted that patents have a time lag of one and a half years from filing to publication, so it is not possible to analyze the situation more recent than one and a half years.
If you want to find out more information, " Patent Integration , You can compare the number of patent applications with competitors in each technical field in a short time by multiplying with other keywords and patent classifications.Please use it for more detailed patent information analysis such as selection of M&A candidate destinations and alliance destinations.
Trends in filing of joint patent applications in the last 3 years (2022 to 2024).
Among the top coapplicants, エフホフマン-ラロシュアーゲー has the highest number of joint applications in the last in the last 3 years (2022 to 2024) with 18 cases, followed by ザリージェンツオブザユニバーシティオブカリフォルニア with 13 cases.
| Name | Cases |
|---|---|
| エフホフマン-ラロシュアーゲー | 18 cases |
| ザリージェンツオブザユニバーシティオブカリフォルニア | 13 cases |
| ギリアードサイエンシーズインコーポレイテッド | 10 cases |
| ノバルティスアーゲー | 8 cases |
| ブリストル-マイヤーズスクイブカンパニー | 8 cases |
| グラクソスミスクラインバイオロジカルズソシエテアノニム | 4 cases |
Trends in filing of joint patent applications for the target period (2014 to 2024).
Among the top coapplicants, ギリアードサイエンシーズインコーポレイテッド has the highest number of joint applications in the last for the target period (2014 to 2024) with 205 cases, followed by エフホフマン-ラロシュアーゲー with 196 cases.
| Name | Cases |
|---|---|
| ギリアードサイエンシーズインコーポレイテッド | 205 cases |
| エフホフマン-ラロシュアーゲー | 196 cases |
| ノバルティスアーゲー | 155 cases |
| ザリージェンツオブザユニバーシティオブカリフォルニア | 149 cases |
| ブリストル-マイヤーズスクイブカンパニー | 125 cases |
| グラクソスミスクラインバイオロジカルズソシエテアノニム | 109 cases |
| メルク・シャープ・エンド・ドーム・コーポレイション | 3 cases |
Top company, Change in the Number of JP Patents
Below is a ranking of the number of JP patent applications by 感染’s top 7 coapplicants over the last 20 years.
Below is a patent map showing the changes in the numbers of JP patent filings by 感染’s top 7 coapplicants over the last 20 years.
Top company Details (JP)
Trends in filing of joint patent applications with エフホフマン-ラロシュアーゲー
感染 filed 196 joint applications with エフホフマン-ラロシュアーゲー for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 113 cases in total) is 18.8, and the median is 20.5. The coefficient of variation (standard deviation/mean) is 0.5, and there have been big fluctuations in the number of filings from year to year.
The number of filings has been decreasing for the last 3 years (2020 to 2023). The highest number of filings in 2017 with 30 cases, and their lowest number in 2014 with 14 cases.
| Index | Value |
|---|---|
| Average | 18.8 patents |
| Std Dev | 9.4 |
| COV | 0.5 |
| Year | Cases | YOY |
|---|---|---|
| 2022 year | 18 cases | -37.9 % |
| 2021 year | 29 cases | +11.54 % |
| 2020 year | 26 cases | +13.04 % |
Trends in filing of joint patent applications with ノバルティスアーゲー
感染 filed 155 joint applications with ノバルティスアーゲー for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 74 cases in total) is 12.3, and the median is 12.5. The coefficient of variation (standard deviation/mean) is 0.6, and there have been relatively large fluctuations in the number of filings from year to year.
The highest number of filings in 2015 with 26 cases, and their lowest number in 2022 with 8 cases.
| Index | Value |
|---|---|
| Average | 12.3 patents |
| Std Dev | 7.4 |
| COV | 0.6 |
| Year | Cases | YOY |
|---|---|---|
| 2022 year | 8 cases | -20.00 % |
| 2021 year | 10 cases | -33.3 % |
| 2020 year | 15 cases | -34.8 % |
Trends in filing of joint patent applications with ブリストル-マイヤーズスクイブカンパニー
感染 filed 125 joint applications with ブリストル-マイヤーズスクイブカンパニー for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 60 cases in total) is 10.0, and the median is 11.5. The coefficient of variation (standard deviation/mean) is 0.5, and there have been big fluctuations in the number of filings from year to year.
The highest number of filings in 2014 with 20 cases, and their lowest number in 2022 with 8 cases.
| Index | Value |
|---|---|
| Average | 10.0 patents |
| Std Dev | 5.1 |
| COV | 0.5 |
| Year | Cases | YOY |
|---|---|---|
| 2022 year | 8 cases | -38.5 % |
| 2021 year | 13 cases | -18.75 % |
| 2020 year | 16 cases | +60.0 % |
Trends in filing of joint patent applications with ギリアードサイエンシーズインコーポレイテッド
感染 filed 205 joint applications with ギリアードサイエンシーズインコーポレイテッド for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 107 cases in total) is 17.8, and the median is 21.0. The coefficient of variation (standard deviation/mean) is 0.6, and there have been big fluctuations in the number of filings from year to year.
The number of filings has been decreasing for the last 3 years (2020 to 2023). The highest number of filings in 2015 with 36 cases, and their lowest number in 2022 with 10 cases.
| Index | Value |
|---|---|
| Average | 17.8 patents |
| Std Dev | 10.2 |
| COV | 0.6 |
| Year | Cases | YOY |
|---|---|---|
| 2022 year | 10 cases | -67.7 % |
| 2021 year | 31 cases | +72.2 % |
| 2020 year | 18 cases | -25.00 % |
Trends in filing of joint patent applications with グラクソスミスクラインバイオロジカルズソシエテアノニム
感染 filed 109 joint applications with グラクソスミスクラインバイオロジカルズソシエテアノニム for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 40 cases in total) is 6.7, and the median is 6.5. The coefficient of variation (standard deviation/mean) is 0.6, and there have been relatively large fluctuations in the number of filings from year to year.
The highest number of filings in 2014 with 22 cases, and their lowest number in 2022 with 4 cases.
| Index | Value |
|---|---|
| Average | 6.7 patents |
| Std Dev | 4.1 |
| COV | 0.6 |
| Year | Cases | YOY |
|---|---|---|
| 2022 year | 4 cases | -33.3 % |
| 2021 year | 6 cases | -14.29 % |
| 2020 year | 7 cases | -41.7 % |
Information on important patents (JP)
The following shows JP patents held by 感染 that have had an invalidation trial against them demanded or an opposition filed against them by a third party, and 感染’s JP patents/patent applications of high importance cited by Examiners in patent examination processes.
By noting the most important patents, you can obtain knowledge of the competitive business environment in which 感染 is placed (e.g., whether it is a fiercely competitive environment or an oligopolistic market and the like). In general, it can be understood that a company with a large number of demands for invalidation trials is developing their business in a business environment where IP disputes are common.
If you want to search for more detailed information, you can use Patent Integration to retrieve and download by company cited patents/patent applications or patents undergoing invalidation trials. You can quickly extract important patents from a patent set that includes multiple competitors by cross-referencing with other keywords and patent classifications. Please consider using it for searches for important patents/patent applications.
Glossary
- Cited
- Indicates that the patent/patent application has been cited (by Examiners) in notices of reasons for rejection in the examination process of other (Japanese, U.S., or European) patent applications. The higher the number of citations, the more important the patent/patent application is considered to be.
- Request for invalidation trial
- Indicates that a third party has requested a procedure to invalidate the patent. It is likely to affect the business of third parties and is considered to be of high importance.
- Opposition
- Indicates that a third party has filed a petition with the Patent Office to hear the validity of the patent again. Like the trial for invalidation, it is considered to be of high importance.
- Information provision
- Indicates that a third party has provided the Patent Office with useful information for examination for the patent filed. It is usually considered to be of high importance because it is done to prevent the patent from being granted.
- Browsing request
- Indicates that a third party has requested the Patent Office to view the patent bag (a set of documents exchanged between the Patent Office and the applicant). The bag is often checked prior to trial for invalidation, opposition, and provision of information, and is considered to be a highly important patent.
Invalidationed Trial cases
List of latest Invalidationed Trial patents
In the last 3 years (2021-11-01 ~ 2024-10-31), there were 5 patents Invalidation Trial from third parties. The average number of Invalidation Trial is 1.0 times. The most recently Invalidation Trial patent is 特許6556767 "ＤＰＰ−４阻害剤（リナグリプチン）を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬" (Invalidation Trial day 2024-03-19) , next is 特許7185426 "Ｓ１Ｐ受容体モジュレーターの投与計画" (Invalidation Trial day 2023-07-10) .
| - | No. | Title | Invalidation Trial days |
|---|---|---|---|
| 1 | 特許6556767 | ＤＰＰ−４阻害剤（リナグリプチン）を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬 | 2024-03-19 |
| 2 | 特許7185426 | Ｓ１Ｐ受容体モジュレーターの投与計画 | 2023-07-10 |
| 3 | 特許7016341 | ＰＤ－１軸結合アンタゴニスト及びＴＩＧＩＴ阻害剤を使用するがんの治療方法 | 2023-03-27 |
| 4 | 特許6896700 | ワクチン組成物 | 2023-01-27 |
| 5 | 特許4414623 | 病原微生物および抗微生物剤の検出法、抗微生物剤の薬効評価法ならびに抗微生物剤 | 2023-01-11 |
Top Patents/Patent Applications with the Highest Number of Invalidationed Trial
Of the patent applications filed in the last 10 years (2014-11-01 to 2024-10-31), 5 patents/patent applications were invalidation trial more than once in the examination process of other patent applications. The mean of the number of invalidation trial is 1.0. The most invalidation trial patent is 特許6335326 "コンジュゲート化莢膜糖類抗原を含む免疫原性組成物およびその使用" (1 times) , and the next most invalidation trial patent is 特許6896700 "ワクチン組成物" (1 times) .
| - | No. | Title | |
|---|---|---|---|
| 1 | 特許6335326 | コンジュゲート化莢膜糖類抗原を含む免疫原性組成物およびその使用 | 1 times |
| 2 | 特許6896700 | ワクチン組成物 | 1 times |
| 3 | 特許6074462 | 抗−ＴＮＦα抗体の投与方法 | 1 times |
| 4 | 特許6302529 | 抗−ＴＮＦα抗体の投与方法 | 1 times |
| 5 | 特許6556767 | ＤＰＰ−４阻害剤（リナグリプチン）を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬 | 1 times |
Oppositioned cases
List of latest Oppositioned patents
In the last 3 years (2021-11-01 ~ 2024-10-31), there were 10 patents Opposition from third parties. The average number of Opposition is 1.0 times. The most recently Opposition patent is 特許7448953 "眼疾患のための細胞モデル及び治療関連出願への相互参照" (Opposition day 2024-04-17) , next is 特許7291217 "足場非依存性細胞およびその使用" (Opposition day 2023-12-14) .
| - | No. | Title | Opposition days |
|---|---|---|---|
| 1 | 特許7448953 | 眼疾患のための細胞モデル及び治療関連出願への相互参照 | 2024-04-17 |
| 2 | 特許7291217 | 足場非依存性細胞およびその使用 | 2023-12-14 |
| 3 | 特許7237544 | 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤 | 2023-09-11 |
| 4 | 特許7038664 | 操作された腫瘍溶解性ウイルス | 2022-09-15 |
| 5 | 特許7031957 | 感染症検査方法 | 2022-09-07 |
| 6 | 特許6999061 | 免疫賦活用組成物、風邪様症状予防剤、及びウイルス感染予防剤 | 2022-07-15 |
| 7 | 特許6933898 | 養子細胞治療製品を製造するための誘導多能性幹細胞の適用 | 2022-03-07 |
| 8 | 特許6942466 | 抗原特異的Ｔ細胞受容体遺伝子を有する多能性幹細胞の製造方法 | 2021-12-27 |
| 9 | 特許6896700 | ワクチン組成物 | 2021-12-06 |
| 10 | 特許6881813 | 核酸ワクチン | 2021-11-30 |
Protested cases
List of latest Protested patents
In the last 3 years (2021-11-01 ~ 2024-10-31), there were 36 patents Protest from third parties. The average number of Protest is 1.4 times. The most recently Protest patent is 特表2024-504870 "含窒素架橋複素環化合物、その調製方法及びその医薬的応用" (Protest day 2024-09-02) , next is 特許7524213 "下痢の防止及び処置における使用のためのビデンスピローサ及びそのファイトケミカル" (Protest day 2024-08-01) .
| - | No. | Title | Protest days |
|---|---|---|---|
| 1 | 特表2024-504870 | 含窒素架橋複素環化合物、その調製方法及びその医薬的応用 | 2024-09-02 |
| 2 | 特許7524213 | 下痢の防止及び処置における使用のためのビデンスピローサ及びそのファイトケミカル | 2024-08-01 |
| 3 | 特開2022-107358 | 二多段式駐車装置とその制御方法 | 2024-07-24 |
| 4 | 特表2022-506635 | オリゴ糖組成物およびその使用方法 | 2024-06-03 |
| 5 | 特開2021-138745 | ワクチン組成物 | 2024-02-27 |
| 6 | 特許7542530 | 緩衝塩及びアミノ酸を含有する粉末、そのような粉末の栄養製品への再構成、並びにそのような栄養製品を使用する方法 | 2024-01-30 |
| 7 | 特開2021-116296 | コロナウイルス感染の治療におけるファビピラビルの使用 | 2023-12-19 |
| 8 | 特開2022-174188 | プレフィルドシリンジ用のシリンジ本体 | 2023-11-07 |
| 9 | 特許7524072 | 敗血症および敗血症性ショックの治療 | 2023-11-06 |
| 10 | 特表2023-524137 | 酸化セルロースを含む組成物 | 2023-09-14 |
| 11 | 特開2023-093482 | Ｓ１Ｐ受容体モジュレーターの投与計画 | 2023-08-28 |
| 12 | 特開2021-126049 | ヒトノロウイルス不活化評価法 | 2023-05-16 |
| 13 | 特開2021-169414 | 歯肉組織内部の歯周病菌に対する歯周病菌抑制剤 | 2023-05-10 |
| 14 | 特許7524214 | 抗体コード配列をセーフハーバー遺伝子座に挿入するための方法および組成物 | 2023-03-24 |
| 15 | 特表2021-504096 | 活性化表面に結合した接着層 | 2023-03-23 |
| 16 | 特開2022-103508 | ＳＡＲＳ－ＣｏＶ－２ウイルス感染抑制剤及びＳＡＲＳ－ＣｏＶ－２ウイルス感染抑制用組成物 | 2023-02-06 |
| 17 | 特表2021-530463 | ｍＴＯＲ阻害剤の無水組成物および使用方法 | 2023-01-19 |
| 18 | 特開2022-030481 | 抗ウイルス剤 | 2022-11-25 |
| 19 | 特表2022-517754 | 菌株、組成物および使用方法 | 2022-10-31 |
| 20 | 特表2022-527833 | 局所用クロトン・レクレリ組成物および急性皮膚軟部組織感染症または皮膚構造感染症の治療におけるそれらの使用 | 2022-10-19 |
Top Patents/Patent Applications with the Highest Number of Protested
Of the patent applications filed in the last 10 years (2014-11-01 to 2024-10-31), 72 patents/patent applications were protest more than once in the examination process of other patent applications. The mean of the number of protest is 1.3. The most protest patent is 特許7123158 "水系塗料組成物、塗膜及び塗装物品" (5 times) , and the next most protest patent is 特許6616332 "マイコプラズマ・ニューモニエの免疫学的検出法及びキット" (5 times) .
| - | No. | Title | |
|---|---|---|---|
| 1 | 特許7123158 | 水系塗料組成物、塗膜及び塗装物品 | 5 times |
| 2 | 特許6616332 | マイコプラズマ・ニューモニエの免疫学的検出法及びキット | 5 times |
| 3 | 特開2021-116296 | コロナウイルス感染の治療におけるファビピラビルの使用 | 4 times |
| 4 | 特開2021-138745 | ワクチン組成物 | 4 times |
| 5 | 特許6616333 | マイコプラズマ・ニューモニエの免疫学的検出法およびキット | 4 times |
Inspectioned cases
List of latest Inspectioned patents
In the last 3 years (2021-11-01 ~ 2024-10-31), there were 292 patents Inspection from third parties. The average number of Inspection is 1.5 times. The most recently Inspection patent is 特表2022-511786 "新規芳香族化合物によるナチュラルキラー細胞およびＩＬＣ３細胞の増殖" (Inspection day 2024-09-24) , next is 特表2021-517895 "ＨＰＶ関連疾患を処置するための方法" (Inspection day 2024-09-19) .
| - | No. | Title | Inspection days |
|---|---|---|---|
| 1 | 特表2022-511786 | 新規芳香族化合物によるナチュラルキラー細胞およびＩＬＣ３細胞の増殖 | 2024-09-24 |
| 2 | 特表2021-517895 | ＨＰＶ関連疾患を処置するための方法 | 2024-09-19 |
| 3 | 特開2023-159105 | マイクロ流体を使用した治療的に活性な細胞を調製する方法 | 2024-09-13 |
| 4 | 特表2024-504870 | 含窒素架橋複素環化合物、その調製方法及びその医薬的応用 | 2024-09-12 |
| 5 | 特表2022-526084 | ３次元定量的位相イメージングを用いる微生物の同定 | 2024-09-09 |
| 6 | 特表2022-500042 | 抗ＨＩＶ抗体１０−１０７４バリアント | 2024-09-06 |
| 7 | 特表2021-519069 | 遺伝子改変リンパ球の製造方法 | 2024-09-06 |
| 8 | 特開2023-071635 | 分子標的薬ｎＣｏＶｓｈＲＮＡ・２ＡＣＥ２の合成方法 | 2024-09-05 |
| 9 | 特表2022-537670 | ＣＡ２の組成物および調整可能な制御方法 | 2024-09-05 |
| 10 | 特開2022-107358 | 二多段式駐車装置とその制御方法 | 2024-08-28 |
| 11 | 特表2023-518552 | ＬＮＰ０２３の結晶形態 | 2024-08-27 |
| 12 | 特表2024-521164 | 感染後自己免疫性糖尿病を治療するための方法 | 2024-08-14 |
| 13 | 特開2023-030014 | チオールイソメラーゼ阻害剤およびその使用 | 2024-08-06 |
| 14 | 特許5586842 | 試料ろ過フィルターを用いる簡易メンブレンアッセイ方法及びキット | 2024-08-01 |
| 15 | 特許7547433 | ワクチンベクターとしての三セグメントピチンデウイルス | 2024-07-29 |
| 16 | 特表2021-504375 | 医療用および美容用の逐次的に低強度音波にさらされるナノ粒子 | 2024-07-17 |
| 17 | 特開2022-084946 | 様々な疾患および障害の治療のためにＭＡＳＰ－１および／またはＭＡＳＰ－２および／またはＭＡＳＰ－３を阻害する組成物および方法 | 2024-07-11 |
| 18 | 特開2022-031469 | 組成物、結合阻害剤、医療機器およびＣＯＶＩＤ－１９の予防方法 | 2024-06-28 |
| 19 | 特開2022-110130 | 新規の阻害剤 | 2024-06-27 |
| 20 | 特表2023-518234 | 伝染病の監視および大流行の検出のためのシステムおよび方法 | 2024-06-18 |
Top Patents/Patent Applications with the Highest Number of Inspectioned
Of the patent applications filed in the last 10 years (2014-11-01 to 2024-10-31), 588 patents/patent applications were inspection more than once in the examination process of other patent applications. The mean of the number of inspection is 1.3. The most inspection patent is 特許6320473 "アロＮＫＴ細胞を用いた免疫療法およびそのためのＴ細胞抗原受容体（ＴＣＲ）遺伝子のα鎖領域が均一なＶα−Ｊαに再構成されている細胞および該細胞由来ＮＫＴ細胞のバンキング" (48 times) , and the next most inspection patent is 特許6616332 "マイコプラズマ・ニューモニエの免疫学的検出法及びキット" (9 times) .
| - | No. | Title | |
|---|---|---|---|
| 1 | 特許6320473 | アロＮＫＴ細胞を用いた免疫療法およびそのためのＴ細胞抗原受容体（ＴＣＲ）遺伝子のα鎖領域が均一なＶα−Ｊαに再構成されている細胞および該細胞由来ＮＫＴ細胞のバンキング | 48 times |
| 2 | 特許6616332 | マイコプラズマ・ニューモニエの免疫学的検出法及びキット | 9 times |
| 3 | 特開2018-131469 | 磁気双極子安定化溶液の使用を含む疾患を処置または改善する方法および行動を向上させる方法 | 9 times |
| 4 | 特許6616333 | マイコプラズマ・ニューモニエの免疫学的検出法およびキット | 9 times |
| 5 | 特開2021-116296 | コロナウイルス感染の治療におけるファビピラビルの使用 | 8 times |
Cited cases
Top Patents/Patent Applications with the Highest Number of Cited
Of the patent applications filed in the last 10 years (2014-11-01 to 2024-10-31), 2,737 patents/patent applications were cited more than once in the examination process of other patent applications. The mean of the number of cited is 2.2. The most cited patent is 特開2020-067939 "感染リスク特定システム、情報端末、及び、感染リスク特定方法" (28 times) , and the next most cited patent is 特許6352974 "ワクチンのための高力価組み換えインフルエンザ・ウィルス" (26 times) .
| - | No. | Title | |
|---|---|---|---|
| 1 | 特開2020-067939 | 感染リスク特定システム、情報端末、及び、感染リスク特定方法 | 28 times |
| 2 | 特許6352974 | ワクチンのための高力価組み換えインフルエンザ・ウィルス | 26 times |
| 3 | 特許7000357 | 免疫調節剤としての複素環化合物 | 24 times |
| 4 | 特許7149276 | ＰＤ－Ｌ１内在化誘導物質としてのテトラヒドロイミダゾ［４，５－Ｃ］ピリジン誘導体 | 24 times |
| 5 | 特許7101678 | 免疫調節剤としての複素環式化合物 | 23 times |
Providing patent information to the media (newspapers, magazines, etc.)
"Patent Integration Report" is a web service provided by "Patent Integration Co., Ltd." operated by patent attorneys who are experts in intellectual property rights. Based on the latest patent data, this is one of the largest patent report services in Japan that provides information on technology trends in various companies and technology fields.
The purpose of this web service is to make intellectual property information familiar to many people, regardless of whether they have an interest in intellectual property rights, and to make use of it.
We actively provide various types of patent information that can be used in various media articles such as newspapers, magazines, and web media. Please feel free to contact us from "Inquiry form for details on the content of patent information that can be provided, conditions for provision, etc. Please contact us.
About this Site
All rights related to the data, documents and charts belong to "an integrated patent search/analysis service provider, Patent Integration". Please specify the source “Patent Integration Report, URL: https://patent-i.com/report/en/" when inserting them into in-house materials, external report materials, etc., regardless of whether they are paid or free of charge.
Patent data is obtained by aggregating and analyzing the latest patent data issued by the Patent Offices of respective countries and jurisdictions and by WIPO. Although we take great care in publishing and analyzing the results, we do not guarantee the correctness of the data. We appreciate your understanding.
If you have any concerns about this service, please feel free to contact us.
All rights to the data, documents, figures and tables are reserved by e-Patent. When publishing internal documents, external reports, etc. (whether paid or free of charge), please use the following URL: https://e-patent.co.jp/.
Please note the following points for use.
e-Patent will not be liable for any damages or losses arising from the use of the global patent application status, ranking information, or population search formula in the "SDGs Global Company Ranking from a Patent Perspective". Items with ● in front of the target are not supported at this time (judged to be difficult to approach from the patent information analysis).
Citation of patent application status and ranking information
There is no problem to cite patent application status and ranking information, but please clearly indicate "Source: e-Patent Co.
Graphs are image data.
Please note that the various graphs are image data, but we cannot provide them in text data.Scope of coverage for each goal/target
- Based on the description of each goal and target of the SDGs, we have set the scope of technologies to be covered based on our and e-Patent's past experience, etc. (in some cases, the search is based on social issues themselves). Therefore, please note that there is a possibility that this "SDGs Global Company Ranking from Patent Perspective" may not cover 100%.
- A population search formula is clearly indicated for each goal/target (database: Patent Integration). You may use the population search formula as it is, or you may improve it by yourself.
- This search covers patents and utility models, including both published and registered patents (design and design patents are excluded). The unit of count is the number of applications, not the number of patent families.
About the name collation and name control of applicants and right holders
- Company rankings are based on the results calculated by "Patent Integration", with Japanese organizations in Japanese and other companies in English (some are in Japanese).
- Company names may be the names of the companies at the time of application, but the results calculated by Patent Integration are used as is. Company names are used as they were at the time of application.
- Because of the fluctuation in the names of companies (i.e., applicant/right holder names in the patent information), there are cases where the same company appears more than once in the top 10. The number of applications filed by the same company in the top 10 is the total number of applications filed by the company.
Credit notation
・MeCab user dictionary for science technology term © National Bioscience Database Center licensed under CC Attribution-Share Alike 4.0 International
Our Commitment to Safety and Security
Patent Integration Co., Ltd. is committed to providing high-quality patent information based on the latest patent data on more than 45 million cases collected from the Patent Offices in Japan, the U.S., Europe, and Taiwan and from PCT publication. 
Patent Integration Co., Ltd. collects the patent data from the Patent Offices in Japan, the U.S., Europe, and Taiwan and from PCT publications to provide it widely in the form of reports so that anyone can check patent information and patent trends with confidence. 
Patent Integration Co., Ltd. is committed to various efforts to enhance the reliability of the information and to allow users to search patent information with confidence.